GlassScriptPhysician profile
Paul Lawrence Haun
NPI 1881980738
$85,328.74
in general payments reported to CMS, 2019-2025
19 companies · $50K in 2025
The $50K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,273 · 2020: $6,200 · 2023: $12K · 2024: $11K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Travel and Lodging: $3,569 · Food and Beverage: $2,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,400.00 |
| Travel and Lodging | $3,569.04 |
| Food and Beverage | $2,886.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $83,170.14 | 2019-2025 | Poteligeo |
| Abbvie INC. | $735.48 | 2023-2025 | |
| Genzyme Corporation | $289.42 | 2023-2025 | |
| Pfizer INC. | $192.78 | 2023-2025 | |
| Janssen Biotech, INC. | $192.11 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $147.68 | 2024-2025 | Sotyktu |
| Amgen INC. | $108.87 | 2024-2025 | Otezla, Otezla |
| Helsinn Therapeutics (U.S.), INC. | $102.12 | 2023-2025 | Valchlor |
| Lilly USA, LLC | $89.06 | 2023-2024 | Taltz, Olumiant |
| Mayne Pharma Commercial LLC | $51.76 | 2025 | |
| Leo Pharma INC. | $49.80 | 2023-2024 | Adbry |
| Verrica Pharmaceuticals INC. | $49.77 | 2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $32.02 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $26.67 | 2023 | Dupixent |
| Medline Industries LP | $20.36 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $20.29 | 2025 | Seysara |
| Ucb, INC. | $18.38 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $17.72 | 2024 | |
| Sun Pharmaceutical Industries INC. | $14.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Haun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.